The 45,500 square foot Class A facility is located at 2 Clarke Drive in Cranbury, NJ.
“The demand for Experic has been driven primarily by the increase of innovation coming from the smaller-sized pharma and biotech companies,” said Eric Bergmann, Experic president and co-founder.
“Coupled with the need for contractors with new technologies that support novel dosage forms and delivery mechanisms, this trend is as much capability driven as it is capacity,” he told us.
The company, which will target the needs of small and mid-sized customers, will deliver traditional oral solid manufacturing as well as packaging for clinical supplies and niche commercial products.
The facility also will provide global supply chain management services.
Additionally, Experic has created a center of excellence surrounding the clinical development of low dose powders and drug product for inhalation (DPI) based on a technology platform from Harro Hofliger GmbH, Bergmann explained.
Upon opening – the date of which will be released later this year – the facility will accommodate processing, storage, and logistics of controlled room temperature (CRT), refrigerated (2-8°C), and frozen (-20°°C and -80°C) materials, as well as Schedule II-V DEA controlled substances.
Bergmann said leadership recruitment began in January and a team of industry professionals has been assembled.
“As we prepare for opening, we continue by hiring the technical and operational talent that will perform our critical day-to-day activities,” he added. “By the end of year two we hope to have created jobs for approximately 100 employees.”
The facility plans were developed in collaboration with Precis Engineering and Jacobswyper Architects.
